Full metadata record
DC FieldValueLanguage
dc.creatorIzco, M. (María)-
dc.creatorVettorazzi, A. (Ariane)-
dc.creatorForcén, R. (Raquel)-
dc.creatorBlesa, J. (Javier)-
dc.creatorToro, M. (María) de-
dc.creatorÁlvarez-Herrera, N. (Natalia)-
dc.creatorCooper, J.M. (J. M.)-
dc.creatorGonzalez-Peñas, E. (Elena)-
dc.creatorLopez-de-Cerain, A. (Adela)-
dc.creatorAlvarez-Erviti, L. (Lydia)-
dc.date.accessioned2022-05-31T09:34:41Z-
dc.date.available2022-05-31T09:34:41Z-
dc.date.issued2021-
dc.identifier.citationIzco, M. (María); Vettorazzi, A. (Ariane); Forcén, R. (Raquel); et al. "Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment". Food and Chemical Toxicology. (152), 2021, 112164es_ES
dc.identifier.issn0278-6915-
dc.identifier.urihttps://hdl.handle.net/10171/63579-
dc.description.abstractSome epidemiological studies with different levels of evidence have pointed to a higher risk of Parkinson’s disease (PD) after exposure to environmental toxicants. A practically unexplored potential etiological factor is a group of naturally-occurring fungal secondary metabolites called mycotoxins. The mycotoxin ochratoxin A (OTA) has been reported to be neurotoxic in mice. To further identify if OTA exposure could have a role in PD pathology, Balb/c mice were orally treated with OTA (0.21, 0.5 mg/kg bw) four weeks and left for six months under normal diet. Effects of OTA on the onset, progression of alpha-synuclein pathology and development of motor deficits were evaluated. Immunohistochemical and biochemical analyses showed that oral subchronic OTA treatment induced loss of striatal dopaminergic innervation and dopaminergic cell dysfunction responsible for motor impairments. Phosphorylated alpha-synuclein levels were increased in gut and brain. LAMP-2A protein was decreased in tissues showing alpha-synuclein pathology. Cell cultures exposed to OTA exhibited decreased LAMP-2A protein, impairment of chaperone-mediated autophagy and decreased alpha-synuclein turnover which was linked to miRNAs deregulation, all reminiscent of PD. These results support the hypothesis that oral exposure to low OTA doses in mice can lead to biochemical and pathological changes reported in PDes_ES
dc.description.sponsorshipThis study was funded by European Regional Development Fund (ERDF) “A way to make Europe” (6FRSABC008), the Government of Navarra (Project-43, 2019 modality A) and European Regional Development Fund (ERDF under Operational Programme for Navarra, 2014–2020). Chromatographic studies were funded by the “Ministerio de Economia, Industria y Competitividad, Agencia Estatal de Investigacion” (AGL2017-85732-R) (MINECO/AEI/FEDER, UE). L.A.E is supported by a Miguel Servet contract (CP15/00200) from ISCIII. F.J.B is supported by a Miguel Servet contract (CP19/00200) from ISCIII.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectParkinson’s diseasees_ES
dc.subjectAlpha-synucleines_ES
dc.subjectOchratoxin Aes_ES
dc.subjectGut-brain axises_ES
dc.subjectChaperone-mediated autophagyes_ES
dc.subjectLAMP-2Aes_ES
dc.titleOral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatmentes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article under the CC BY-NC-ND licensees_ES
dc.identifier.doi10.1016/j.fct.2021.112164-
dadun.citation.number152es_ES
dadun.citation.publicationNameFood and Chemical Toxicologyes_ES
dadun.citation.startingPage112164es_ES

Files in This Item:
Thumbnail
File
1-s2.0-S0278691521001976-main.pdf
Description
Size
7.58 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.